Madrigal’s $1 Billion PNPLA3 Bet Rewrites the MASH Playbook — And Leaves Competitors Chasing a Genetically Defined Market
Madrigal licenses ARO-PNPLA3 from Arrowhead for up to $1B, targeting a PNPLA3 mutation affecting ~30% of F2–F3 MASH patients,...